 phase II studi high-dos continu infus lymphokine-activ killer cell patient metastat melanoma thirty-thre patient metastat melanoma phase II studi intraven continu infus ivci lymphokine-activ killer lak cell dose optim prime dose lak-cel induct lak-cel dose ivci schedul previou phase trial CI schedul evalu postul reduct toxic possibl prolong infus rebound lymphocytosi lak-cel gener dose schedul patient similar age perform statu site diseas previou trial patient assess respons toxic patient partial respons month durat signific respons signific toxic hypotens pressor dyspnea renal insuffici hepat dysfunct cardiac arrhythmia toxic cessat infus death first day treatment infect central line lak cell tumor tumor-rel hemorrhag toxic high compar previou studi high-dos IV bolu schedul ivci schedul high-dos bolu lak cell nonrandom sequenti studi patient advanc melanoma CI efficaci